Tribute's portfolio includes Fibricor, Bezalip
SR and Visken/Viskazide for various cardiovascular indications; Cambia and Fiorinal and Fiorinal C for acute migraines and tension headaches, respectively; and a range of other specialty products.
G1046) or Bezalip (100 [micro]mol/l; bezafibrate; Roche Molecular Biochemicals, Almere, The Netherlands) before they were exposed to 500 [micro]mol/l OA (Sigma-Aldrich Co., St.
Another group of HFD-fed hamsters was treated orally with Bezalip (10 mg/kg/day) dissolved in distilled water, a dose based on a study indicating that long-term treatment ameliorates hyperlipidemia and fatty liver in a rat model of NAFLD (Schmilovitz-Weiss et al.
The deposition of lipid and increases in Choi and TG content in OA-treated HepG2 cells were also abolished by preincubation with Bezalip (Fig.
Bezalip (100 [micro]mol/l) almost eliminated OA-evoked production of MCP-1, TNF-[alpha], IL-1[beta], and IL-6 in HepG2 cells.
Similar results were seen in HFD-fed hamsters treated with Bezalip (10 mg/kg/day) (Table 2).
Treatment of HFD-fed hamsters with -gingerol (100 mg/kg/day) or Bezalip (10 mg/kg/day) decreased HOMA-IR and plasma leptin and insulin levels (Table 2).
Plasma TC, TG, LDL-C, and FFA levels were reduced by 39.6%, 30.6%, 58.6%, and 38.3% respectively, in Bezalip (10 mg/kg/day)-treated HFD-fed hamsters compared to their vehicle-treated counterparts (Table 2).
Bezalip (10 mg/kg/day) treatment also reduced hepatic TC and TG levels to 32.6% and 39.9% of that in vehicle-treated HFD-fed hamsters, respectively (Table 2).
Bezalip (10 mg/kg/day) treatment also improved hepatic steatosis and reduced hepatic inflammation in HFD-fed hamsters (Fig.